Spots Global Cancer Trial Database for sacituzumab tirumotecan
Every month we try and update this database with for sacituzumab tirumotecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | NCT06428409 | Colorectal Canc... Pancreatic Duct... Biliary Tract C... | Sacituzumab tir... Fluorouracil (5... Leucovorin (LV)... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | NCT06312176 | Breast Neoplasm... | Sacituzumab tir... Pembrolizumab Paclitaxel Nab-paclitaxel Capecitabine Liposomal doxor... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | NCT06356311 | Gastroesophagea... | Sacituzumab tir... Trifluridine-Ti... Irinotecan Paclitaxel Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | NCT06170788 | Non-small Cell ... | Sacituzumab tir... Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | NCT06132958 | Endometrial Can... | Sacituzumab tir... Doxorubicin Paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | NCT05319730 | Esophageal Squa... | Paclitaxel Irinotecan Pembrolizumab MK-4830 Lenvatinib Sacituzumab tir... Antihistamine H2 Receptor Ant... Acetaminophen (... Dexamethasone (... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | NCT06312137 | Non Small Cell ... | Sacituzumab tir... Pembrolizumab Cisplatin Pemetrexed Gemcitabine Carboplatin Paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | NCT06049212 | Non-small Cell ... Solid Tumors Programmed Cell... Programmed Cell... Programmed Cell... | Sacituzumab tir... Pembrolizumab Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | NCT06074588 | Non-small Cell ... | Sacituzumab tir... Docetaxel Pemetrexed | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
